Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A 24-week Treatment, Multi-center, Randomized, Double-blind, Double-dummy, Parallel Group Study to Compare Umeclidinium/Vilanterol, Umeclidinium, and Salmeterol in Subjects With Chronic Obstructive Pulmonary Disease (COPD)

Next Previous
Trial Profile

A 24-week Treatment, Multi-center, Randomized, Double-blind, Double-dummy, Parallel Group Study to Compare Umeclidinium/Vilanterol, Umeclidinium, and Salmeterol in Subjects With Chronic Obstructive Pulmonary Disease (COPD)

Status: Completed
Phase of Trial: Phase IV

Latest Information Update: 01 Sep 2023

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Salmeterol (Primary) ; Umeclidinium (Primary) ; Umeclidinium/vilanterol (Primary)
  • Indications Chronic obstructive pulmonary disease
  • Focus Therapeutic Use
  • Acronyms EMAX
  • Sponsors GlaxoSmithKline; GSK

Most Recent Events

  • 04 Aug 2021 Results of a prespecified analysis of the EMAX trial, published in the Advances in Therapy
  • 20 May 2021 Results of post hoc analysis assessing cost-effectiveness of UMEC/VI versus UMEC or SAL from a UK payer perspective in patients with COPD and no exacerbation history in the EMAX trial presented at the 26th Annual International Meeting of the International Society for Pharmacoeconomics and Outcomes Research
  • 20 May 2020 Results of post hoc analysis investigating its corollary, the clinically important improvement (CII), which is a composite endpoint that requires concordant minimum clinically important differences (MCID) in ≥2 patient-reported outcomes (PROs), presented at the 116th International Conference of the American Thoracic Society.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top